Wnt signaling pathway: implications for therapy in lung cancer and bone metastasis

Cancer Lett. 2014 Oct 10;353(1):8-16. doi: 10.1016/j.canlet.2014.07.010. Epub 2014 Jul 17.

Abstract

Lung cancer remains a major worldwide health problem and patients have high rate of metastasis including bone. Although pathologic characteristics of this disease are clear and well established, much remains to be understood about this tumor, particularly at the molecular signaling level. Secreted signaling molecules of the Wnt family have been widely investigated and found to play a prominent role to induce human malignant diseases, such as breast and prostate cancer. A variety of studies have also demonstrated that the Wnt signaling pathway is closely associated with bone malignancies including osteosarcoma, multiple myeloma, and breast or prostate cancer induced bone metastasis. The aim of this review is to provide a summary regarding the role of the Wnt signaling pathway in lung cancer and bone metastasis, highlighting the aberrant activation of Wnt in this malignancy. We also discuss the potential therapeutic applications for the treatment of lung cancer and cancer induced bone metastasis targeting the Wnt pathway.

Keywords: Beta-catenin; Bone metastasis; Lung cancer; Wnt signaling.

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use
  • Bone Neoplasms / genetics
  • Bone Neoplasms / metabolism*
  • Bone Neoplasms / secondary
  • Bone Neoplasms / therapy
  • Gene Expression Regulation, Neoplastic
  • Genetic Therapy
  • Humans
  • Lung Neoplasms / genetics
  • Lung Neoplasms / metabolism*
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy
  • Molecular Targeted Therapy
  • Prognosis
  • Wnt Signaling Pathway* / drug effects
  • Wnt Signaling Pathway* / genetics

Substances

  • Antineoplastic Agents